Celldex Therapeutics, Inc. — Director's Dealing 2017

Jun 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2017-06-15

Reporting Person: Wright Richard M. (Sr. VP & CCO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-15	Incentive Stock Option (right to buy)	$2.32	A	75000	Acquired	2027-06-15	Common Stock (75000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.